Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 14, 2014 - Issue 2
Submit an article Journal homepage
92
Views
7
CrossRef citations to date
0
Altmetric
Research Reports

The power of r – pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?

Panagiotis PetrouHealthCare Management Program, Open University of Cyprus, PO Box 12794, 2252, Latsia, CyprusCorrespondence[email protected]
Pages 289-300 | Published online: 03 Mar 2014

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Panagiotis Petrou. (2015) Cost-effectiveness analysis of axitinib through a probabilistic decision model. Expert Opinion on Pharmacotherapy 16:8, pages 1233-1243.
Read now
Panagiotis Petrou. (2014) Pharmacoeconomics in the years of crisis: a solution or just a resolution? A Cyprus perspective. Expert Review of Pharmacoeconomics & Outcomes Research 14:5, pages 627-636.
Read now

Articles from other publishers (5)

Panagiotis Petrou. (2015) An Interrupted Time-Series Analysis to Assess Impact of Introduction of Co-Payment on Emergency Room Visits in Cyprus. Applied Health Economics and Health Policy 13:5, pages 515-523.
Crossref
Olivier J WoutersPanos G Kanavos. (2015) Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Bulletin of the World Health Organization 93:9, pages 606-613.
Crossref
Panagiotis Petrou & Michael A. Talias. (2015) Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market. Value in Health Regional Issues 7, pages 67-73.
Crossref
Panagiotis Petrou & Sotiris Vandoros. (2015) Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment. Health Policy 119:5, pages 563-568.
Crossref
Panagiotis Petrou & Michael A Talias. (2014) A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer. Cost Effectiveness and Resource Allocation 12:1, pages 12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.